Savaysa Shows The Good And Bad Of Being Late In Class
Executive Summary
As Daiichi’s experience suggests, sponsors of later-in-class products may face unfavorable efficacy comparisons to their earlier-approved brethren and challenges in qualifying for a priority review; however, risk management obligations may be less burdensome than for first-in-class products.
You may also be interested in...
Pivotal Trials Are Cheaper For Unmet Needs And Orphan Drugs, JAMA Study Finds
Analysis of clinical trial costs for CDER’s 2015-2016 novel therapeutic approvals finds pivotal studies are most expensive when a new agent has a similar benefit to already marketed products with well-established clinical profiles.
Behind The Approval Letter: Drug Review Profiles
A listing of the Drug Review Profile series articles published in the Pink Sheet.
Savaysa Clinical Development
A timeline chronicling the development of Daiichi Sankyo’s Factor Xa inhibitor edoxaban for stroke risk reduction, deep vein thrombosis and pulmonary embolism indications.